Smartwatch with heart rate monitor icon on colorful diagonal striped background
Medtech Case Study

Embedding Sustainable Patient Engagement in Research and Development: A Grassroots Effort

Pharmaceutical Company Collaborates with Patient Organizations to Incorporate Patient Feedback into Company-Wide Research and Development Efforts
 

Source
VOZ Advisors

Link
Embedding Sustainable Patient Engagement in R&D: A Grassroots Effort to Organization-Wide Change at Incyte Corporation
 

Description of Case Study

Incyte Corporation, a global pharmaceutical company, sought to develop a consistent, sustainable path to incorporating patient input into clinical development. In late 2021, two internal champions in clinical operations launched a one-year pilot patient council, partnering with consulting firm VOZ Advisors and recruiting patient/care partner experts across hematology, oncology, myeloproliferative neoplasms, and dermatology/autoimmunity, with attention to racial, ethnic, geographic, age, and gender diversity. Over seven engagements, the council reviewed study protocols and informed consent forms (ICFs), a plain-language summary, a dermatology study dosing diary, and preferred methods for learning about clinical trials. Based on pilot results, Incyte expanded the council to include lay patients and additional therapeutic areas, formalized a patient engagement playbook, created a centralized repository of patient insights, and routed all patient/advocacy-organization outreach through a single public affairs contact. By 2025, the council had grown its engagement activity substantially, and Incyte instituted a company-wide requirement that all studies either directly engage the patient council or incorporate relevant insights from the repository.
 

Quick Facts

Organization name: Incyte Corporation
Organization type: pharmaceutical company
Product category: pharmaceutical/biological product
Region(s) of patient engagement activities: North America: United States
Total product life cycle stage(s): discovery/preclinical; clinical/testing; adoption; post-
approval surveillance/monitoring

 

Product Type(s)

  • pharmaceutical/biological product
     

Product Medical Specialty Area(s)

  • hematology
  • immunology
  • other (oncology, dermatology)
     

Stakeholders

  • pharmaceutical company: internal discovery/research and development (R&D) teams
  • pharmaceutical company: internal clinical affairs/R&D teams
  • pharmaceutical company: internal medical affairs teams
  • patients and caregivers, patient organizations
  • other: consulting firm
     

Methods and Sources of Patient Input

  • patient advisory boards
  • patient advocacy organizations
  • interviews/focus groups/surveys
  • patient-sensitive design controls
     

Impact of Patient Engagement

  • Direct improvements to study materials and processes: Initially, the one-year pilot of the patient council produced study protocol and ICF updates, plain-language summary improvements, dosing diary updates, clinical trial website recommendations, and input on the use of Google Ads for trial awareness.
  • Development of a patient engagement playbook: The success of the pilot effort led to company-wide adoption of patient engagement processes and the development of a company patient engagement playbook.
  • Company-wide adoption of patient engagement: Recognition of the patient council’s value led the company to require that all studies either engage the patient council or otherwise incorporate patient input.
  • Cross-functional accessibility of patient insights: Additionally, patient insights from across the organization became accessible via a repository for cross-functional teams to reference.
  • Cultural and organizational shift: Ultimately, a pilot initiative transformed into a structured approach to incorporate patient feedback into the development of all future products.
     

Lessons Learned

  • A single awareness event does not drive uptake; proactive outreach does: A one-time “Lunch and Learn” to promote the playbook and council was insufficient to spark organization-wide uptake. Engagement increased substantially only after the team proactively identified studies approaching critical milestones (e.g., protocol submission) and contacted study teams directly.
  • Direct exposure builds buy-in: Team members who observed council meetings shifted from viewing patient engagement as a “nice to have” to seeing it as critical to study success, becoming internal champions.
  • A single point of contact prevents the overburdening of patient groups: Routing recruitment outreach through one public affairs contact avoided duplicate or competing requests to patient organizations and supported recruitment of underrepresented communities.
  • A shared insights repository avoids redundant requests and demonstrates value: Centralizing and categorizing council feedback by topic let teams review prior insights before requesting new input and helped identify the types of feedback most often needed.
  • Closing the feedback loop sustains participation: Reporting back to the council after each engagement on how (or whether) their input was applied helped build trust and maintain high participation over time.
  • Leadership buy-in follows demonstrated value: Tying patient engagement to organizational goals and leadership’s direct observation of improvements to study materials was central to securing the resources and mandate for company-wide expansion.